Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.55 |
| ▸ | BRAF | P15056 | 11/20 | 0.54 |
| ▸ | RAF1 | P04049 | 6/20 | 0.49 |
| ▸ | PYGL | P06737 | 1/20 | 0.48 |
| ▸ | PYGM | P11217 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | GCK | P35557 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355383 | 0.89 | KDR (0.50) | KDRBRAFRAF1EPHX2RET | |
| SCHEMBL6478594 | 0.88 | GCK (0.51) | KDRBRAFRAF1PYGLPYGM | |
| SCHEMBL19878538 | 0.85 | KDR (0.51) | KDRBRAFRAF1EPHX2RET | |
| SCHEMBL29397198 | 0.85 | KDR (0.51) | KDRBRAFRAF1EPHX2RET | |
| SCHEMBL4373389 | 0.83 | KDR (0.52) | KDRBRAFRAF1EPHX2RET | |
| SCHEMBL18681347 | 0.82 | BRAF (0.70) | KDRBRAFRAF1EPHX2GCK | |
| SCHEMBL2746228 | 0.82 | KDR (0.64) | KDRBRAFRAF1RET | |
| SCHEMBL940461 | 0.81 | KDR (0.62) | KDRBRAFRAF1EPHX2RET | |
| SCHEMBL6426864 | 0.81 | KDR (0.50) | KDRBRAFRAF1EPHX2GCK | |
| SCHEMBL12355376 | 0.81 | KDR (0.50) | KDRBRAFRAF1EPHX2GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105272911-B | A kind of preparation method of Sorafenib Tosylate | 山东罗欣药业集团恒欣药业有限公司 | 2018-11-06 | — | — | CN | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-2004631-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | Merck Patent GmbH (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2002062763-A2 | INHIBITION OF RAF KINASE USING QUINOLYL ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | KDR 993/4885BRAF 39/4885RAF1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.